Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) Price Target at $13.45

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given an average recommendation of “Moderate Buy” by the thirteen brokerages that are covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $14.85.

HIMS has been the subject of a number of recent research reports. SVB Leerink initiated coverage on Hims & Hers Health in a research report on Monday, February 26th. They issued a “market perform” rating and a $10.00 target price for the company. Jefferies Financial Group reissued a “hold” rating and issued a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday. Truist Financial upped their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a report on Tuesday, February 27th. Imperial Capital upgraded shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 target price for the company in a research note on Wednesday, February 28th. Finally, Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price target on the stock.

Insider Buying and Selling

In other news, CEO Andrew Dudum sold 50,361 shares of Hims & Hers Health stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total transaction of $822,898.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Andrew Dudum sold 50,361 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $16.34, for a total transaction of $822,898.74. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Soleil Boughton sold 4,080 shares of Hims & Hers Health stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The disclosure for this sale can be found here. Insiders sold a total of 673,335 shares of company stock worth $8,452,208 over the last ninety days. 31.63% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently modified their holdings of the company. Graham Capital Management L.P. grew its position in Hims & Hers Health by 39.4% during the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock valued at $2,141,000 after acquiring an additional 96,277 shares during the last quarter. Swiss National Bank boosted its stake in shares of Hims & Hers Health by 9.2% in the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after purchasing an additional 26,100 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after purchasing an additional 428,671 shares during the last quarter. Bank of New York Mellon Corp raised its position in Hims & Hers Health by 11.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock worth $3,551,000 after purchasing an additional 58,288 shares during the period. Finally, Must Asset Management Inc. bought a new stake in Hims & Hers Health in the third quarter worth $1,596,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $12.69 on Wednesday. The company has a market capitalization of $2.72 billion, a PE ratio of -115.36 and a beta of 0.91. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16. The company has a 50-day simple moving average of $13.36 and a 200 day simple moving average of $9.77.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The company had revenue of $246.60 million during the quarter, compared to analyst estimates of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. Hims & Hers Health’s quarterly revenue was up 47.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) EPS. As a group, analysts forecast that Hims & Hers Health will post 0.1 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.